By Dr. Moxit Shah, DM Endocrinologist
Vishuddha Endocrine Clinic, Ahmedabad
Weight loss injections have changed the way doctors approach obesity and weight-related metabolic problems. Medicines such as semaglutide and tirzepatide can reduce appetite, improve satiety and produce clinically meaningful weight loss when prescribed appropriately.
However, these medicines are not suitable for everyone, and choosing between semaglutide and tirzepatide should not be based simply on which injection is more popular.
At Vishuddha Endocrine Clinic, Ahmedabad, weight-management treatment is individualized according to your BMI, waist circumference, diabetes status, metabolic health, medications, medical history, nutritional status and weight-loss goals.
7
What are weight loss injections?
The term “weight loss injection” generally refers to injectable medicines that influence appetite, food intake and metabolic pathways.
Two important medicines are:
- Semaglutide – a GLP-1 receptor agonist
- Tirzepatide – a dual GIP/GLP-1 receptor agonist
They are used as part of a broader weight-management program that may include nutrition, physical activity, resistance training, behavioral support and regular medical follow-up.
The American Diabetes Association’s 2026 guidance identifies semaglutide and tirzepatide among the higher-efficacy pharmacological options for people with diabetes and overweight or obesity.
How do semaglutide and tirzepatide help with weight loss?
These medicines work partly by influencing the hormonal signals involved in appetite and metabolism.
Semaglutide
Semaglutide activates the GLP-1 receptor.
It can:
- Reduce appetite
- Increase feelings of fullness
- Reduce food intake
- Slow gastric emptying
- Improve blood glucose control
- Support clinically meaningful weight loss
Clinical trials of semaglutide for chronic weight management have demonstrated substantial weight reduction compared with placebo when combined with lifestyle intervention.
Tirzepatide
Tirzepatide activates both:
- GIP receptors
- GLP-1 receptors
This dual mechanism contributes to its effects on appetite, food intake, glucose metabolism and body weight.
In the SURMOUNT-5 trial, adults with obesity without type 2 diabetes receiving maximum tolerated doses of tirzepatide had greater average reductions in body weight and waist circumference than those receiving semaglutide over 72 weeks.
Important: Results from a clinical trial do not mean that every individual will lose the same amount of weight.
Semaglutide vs Tirzepatide: What is the difference?
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Main mechanism | GLP-1 receptor agonist | GIP + GLP-1 receptor agonist |
| Appetite reduction | Yes | Yes |
| Weight loss | Significant | Significant |
| Blood glucose improvement | Yes | Yes |
| GI side effects | Common | Common |
| Dose escalation | Gradual | Gradual |
| Suitable for everyone? | No | No |
| Long-term treatment may be required | Yes | Yes |
The SURMOUNT-5 trial directly compared the two medicines in adults with obesity without diabetes and found greater average weight and waist reduction with tirzepatide. This does not mean that tirzepatide is automatically the appropriate treatment for every patient.
The choice should take into account the individual’s medical history, treatment goals, tolerability, contraindications, other medications and access to treatment.
Who may benefit from weight loss medication?
Weight-management medication is generally considered when lifestyle measures alone are insufficient and the person has clinically significant excess weight or weight-related complications.
Depending on the specific medicine and approved indication, treatment may be considered in adults with obesity or overweight accompanied by weight-related medical conditions.
For example, current regulatory documentation for weight-management indications includes criteria such as:
- BMI ≥30 kg/m², or
- BMI ≥27 kg/m² with at least one weight-related comorbidity
such as hypertension, type 2 diabetes or dyslipidemia.
However, drug-label eligibility and clinical assessment are not exactly the same thing. An endocrinologist should assess the entire metabolic profile rather than prescribing an injection based only on a BMI number.
What about Indians and BMI?
BMI needs to be interpreted in the context of ethnicity and body composition.
The 2026 ADA obesity standards recognize lower BMI thresholds for identifying excess adiposity in people of Asian background. For Asian adults, the standards use BMI ≥27.5 kg/m² as one criterion for obesity, while also considering measures such as waist circumference and waist-to-height ratio.
This is particularly relevant when evaluating Indian patients because metabolic complications can occur at lower BMI levels.
Therefore, your treatment decision should consider:
- BMI
- Waist circumference
- Abdominal obesity
- Blood glucose
- HbA1c
- Blood pressure
- Lipid profile
- Fatty liver/MASLD
- Sleep apnea
- Cardiovascular risk
- Family history
- Previous weight-loss attempts
How much weight can you lose?
There is no single guaranteed percentage of weight loss.
Response varies according to:
- Starting weight
- Presence of diabetes
- Dose reached
- Duration of treatment
- Diet
- Physical activity
- Sleep
- Genetics
- Medication adherence
- Other medical conditions
In the SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide over 72 weeks in adults with obesity without diabetes.
The goal should therefore not be simply “maximum weight loss.”
A good weight-management plan should also aim to improve:
Waist circumference + blood glucose + blood pressure + metabolic health + physical function + quality of life.
The ADA 2026 guidance notes that even 5–7% weight loss can improve glycemia and cardiovascular risk factors, while weight loss exceeding 10% often provides additional benefits.
Are weight loss injections safe?
When appropriately prescribed and monitored, these medicines can be useful tools for obesity treatment.
However, they are not completely free of side effects.
Common side effects
The most common include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal discomfort
- Acid reflux
- Reduced appetite
These symptoms are often more noticeable during dose escalation.
Starting with a low dose and gradually increasing the dose can improve tolerability. The ADA recommends individualizing dose escalation rather than assuming that every patient needs the maximum approved dose.
Who should be particularly cautious?
A medical assessment is important before starting treatment in people with conditions such as:
- Significant gastrointestinal disease
- Gastroparesis
- Previous pancreatitis
- Gallbladder disease
- Certain diabetic eye complications
- Pregnancy or plans for pregnancy
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia type 2
The precise contraindications and warnings depend on the individual medicine and product label.
People taking insulin or sulfonylureas may also require adjustment of their diabetes medication because adding a GLP-1-based medicine can alter hypoglycemia risk.
Do weight loss injections replace diet and exercise?
No.
Medication works best as part of a comprehensive weight-management program.
A good treatment plan may include:
1. Nutrition
Focus on:
- Adequate protein
- Vegetables and fiber-rich foods
- Appropriate portions
- Minimally processed foods
- Adequate hydration
Large, high-fat meals may worsen gastrointestinal symptoms during treatment.
2. Resistance training
Resistance exercise is particularly important during substantial weight loss because maintaining muscle mass is an important component of healthy weight reduction.
3. Aerobic activity
Walking, cycling, swimming or other suitable aerobic activities can improve cardiovascular fitness and metabolic health.
4. Sleep
Poor sleep can make appetite regulation and weight management more difficult.
5. Regular monitoring
Weight management should not stop after prescribing the injection. Your doctor may monitor:
- Weight
- Waist circumference
- Blood pressure
- Blood glucose
- HbA1c
- Lipids
- Liver parameters when appropriate
- Nutritional status
- Side effects
- Muscle preservation
What happens if you stop the injection?
This is one of the most important questions patients should ask before starting treatment.
Obesity is considered a chronic, relapsing disease. Stopping effective pharmacotherapy can result in significant weight recurrence in some patients.
The ADA 2026 Standards note that studies of discontinuation of semaglutide and tirzepatide have shown recurrence of a substantial proportion of lost weight, together with reversal of some cardiometabolic improvements.
This is why weight-management treatment should be planned as a long-term strategy, rather than viewed as a short course of injections.
Can people with diabetes use these medicines?
Yes. In fact, GLP-1-based therapies and tirzepatide can have important roles in people with type 2 diabetes who also have overweight or obesity.
Potential benefits include:
- Lower blood glucose
- Lower HbA1c
- Weight loss
- Reduced insulin requirements in some patients
- Cardiometabolic benefits depending on the medicine and patient’s risk profile
The ADA recommends considering weight-management pharmacotherapy in people with diabetes and overweight/obesity alongside lifestyle intervention.
Should you choose semaglutide or tirzepatide?
There is no single injection that is appropriate for everyone.
An endocrinologist may consider:
- Your weight and BMI
- Waist circumference
- Diabetes status
- HbA1c
- Cardiovascular risk
- Kidney function
- Liver disease
- Gastrointestinal symptoms
- Current medications
- Previous response to weight-loss treatment
- Side-effect tolerance
- Pregnancy plans
- Cost and availability
- Long-term treatment preferences
The aim is not simply to choose the most powerful medicine. The aim is to choose a treatment strategy that is effective, safe, sustainable and appropriate for the individual patient.
Weight Loss Injection Consultation in Ahmedabad
If you are considering semaglutide, tirzepatide or another medical weight-loss treatment, avoid starting injections on your own or using medicines obtained from unverified sources.
At Vishuddha Endocrine Clinic, Dr. Moxit Shah provides endocrinology-focused assessment for:
- Obesity and overweight
- Medical weight management
- Diabetes and prediabetes
- Thyroid disorders
- Insulin resistance
- Fatty liver associated with metabolic disease
- PCOS-related metabolic problems
- GLP-1 and GIP/GLP-1 treatment
The treatment plan is individualized rather than based solely on the number on the weighing scale.
Dr. Moxit Shah
DM Endocrinologist
Vishuddha Endocrine Clinic, Ahmedabad
📞 +91 99799 92797
📍 Elite Magnum, Bhuyangdev Cross Road, Ahmedabad
🌐 endocrinologistinahmedabad.com
Frequently Asked Questions
1. What is the best weight loss injection?
Semaglutide and tirzepatide are both effective evidence-based options, but the appropriate medicine depends on the individual’s medical profile. Clinical trials have shown greater average weight loss with tirzepatide than semaglutide in a direct comparison among adults with obesity without diabetes.
2. Can I take a weight loss injection without diabetes?
Yes. Some injectable medicines are specifically used for chronic weight management in appropriate adults with obesity or overweight with weight-related comorbidities. Eligibility depends on the specific medicine and approved indication.
3. Can I take semaglutide or tirzepatide if I have prediabetes?
Some people with prediabetes and excess weight may benefit from obesity treatment, particularly when lifestyle intervention alone is insufficient. Studies have shown that several obesity medications, including semaglutide and tirzepatide, can reduce progression to type 2 diabetes in studied populations.
4. Do I have to follow a diet while taking the injection?
Yes. Medication should complement—not replace—healthy eating and physical activity.
5. How long do I need to take the injection?
The duration varies. Because obesity is a chronic disease, some people require long-term treatment to maintain weight loss and metabolic benefits.
6. Can weight come back after stopping?
Yes. Weight regain can occur after discontinuation, which is why stopping treatment should be discussed with your treating doctor and followed by an appropriate maintenance strategy.
Final Takeaway
Semaglutide and tirzepatide have become important tools in modern medical weight management, but they are not “quick-fix” injections.
The best results come from combining appropriate medication with:
Individualized nutrition + physical activity + resistance training + medical monitoring + long-term weight-management planning.
If you are considering a weight loss injection in Ahmedabad, an endocrinologist can help determine whether medication is appropriate and which treatment strategy fits your medical profile.
Dr. Moxit Shah, DM Endocrinologist
Vishuddha Endocrine Clinic, Ahmedabad
